Arg-Gly-Asp-Cys
目录号 : GC30186An RGD-containing tetrapeptide
Cas No.:109292-46-8
Sample solution is provided at 25 µL, 10mM.
H-Arg-Gly-Asp-Cys-OH is a tetrapeptide that contains the arginine-glycine-aspartate (RGD) motif, a sequence that acts as a recognition site for various adhesion proteins.1 It inhibits the binding of fibrinogen to endothelial cells and ADP-stimulated platelets with IC50 values of 320 and 35 ?M, respectively.2 Implantation of titanium rods coated with H-Arg-Gly-Asp-Cys-OH increases bone formation in rat femurs.3 H-Arg-Gly-Asp-Cys-OH has been conjugated to polyethylenimine to improve gene transfection efficiency.4
1.Park, H.S., Kim, C., and Kang, Y.K.Preferred conformations of RGDX tetrapeptides to inhibit the binding of fibrinogen to plateletsBiopolymers63(5)298-313(2002) 2.Tranqui, L., Andrieux, A., Hudry-Clergeon, G., et al.Differential structural requirements for fibrinogen binding to platelets and to endothelial cellsJ. Cell Biol.108(6)2519-2527(1989) 3.Ferris, D.M., Moodie, G.D., Dimond, P.M., et al.RGD-coated titanium implants stimulate increased bone formation in vivoBiomaterials20(23-24)2323-2331(1999) 4.Kunath, K., Merdan, T., Hegener, O., et al.Integrin targeting using RGD-PEI conjugates for in vitro gene transferJ. Gene Med.5(7)588-599(2003)
Cell experiment: | Human precursor dermal fibroblasts (HDF, human dermal progenitor cells, 12 week male donor) are use in the assay. WST-1 assay is used to assess the viability of HDF when incubated with chitosan derivatives. For this study, HDF are seeded in a 96-well plate at a density of 6×103 cells/cm2. To each well, 100 μL of cell suspension is added and incubated for 48 h in order to allow cell attachment. DMEM is then replaced by 100 μL of CMTMC and RGDC-DAH-CMTMC suspension at concentrations of 0.25 mg/mL, 0.5 mg/mL and 1 mg/mL, respectively. Cell viability under polymer incubation is evaluated during 2, 4 and 7 days. SDS (1%) is used as negative control. The polymer solution is changed every 3 days. 100 μL of WST-1 (1:10 dilution in DMEM) are added in each well after removing the polymer suspension and incubated for 0.5-2 h. Absorbance is recorded with a BioTek Microplate reader at two different wavelengths (450 and 690 nm). The viability is presented as percentage compared to the positive control group (cells in DMEM supplemented with 10% fetal calf serum). All experiments are carried out in triplicates. |
References: [1]. Patrulea V, et al. Peptide-decorated chitosan derivatives enhance fibroblast adhesion and proliferation in wound healing. Carbohydr Polym. 2016 May 20;142:114-23. |
Cas No. | 109292-46-8 | SDF | |
Canonical SMILES | Arg-Gly-Asp-Cys | ||
分子式 | C15H27N7O7S | 分子量 | 449.48 |
溶解度 | Water : ≥ 50 mg/mL (111.24 mM) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.2248 mL | 11.124 mL | 22.2479 mL |
5 mM | 0.445 mL | 2.2248 mL | 4.4496 mL |
10 mM | 0.2225 mL | 1.1124 mL | 2.2248 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet